Dimensional Fund Advisors’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.5M Buy
960,056
+207,913
+28% +$2.6M ﹤0.01% 2244
2025
Q4
$9.73M Buy
752,143
+186,380
+33% +$2.39M ﹤0.01% 2294
2025
Q3
$7.31M Buy
565,763
+539,609
+2,063% +$7.21M ﹤0.01% 2413
2025
Q2
$466K Buy
26,154
+847
+3% +$14.8K ﹤0.01% 3006
2025
Q1
$452K Sell
25,307
-446
-2% -$10.1K ﹤0.01% 3016
2024
Q4
$768K Sell
25,753
-3,016
-10% -$63.8K ﹤0.01% 2961
2024
Q3
$450K Sell
28,769
-895
-3% -$16.2K ﹤0.01% 3057
2024
Q2
$509K Sell
29,664
-785
-3% -$13.8K ﹤0.01% 3024
2024
Q1
$476K Sell
30,449
-6,762
-18% -$99.4K ﹤0.01% 3052
2023
Q4
$557K Buy
37,211
+2,439
+7% +$32.6K ﹤0.01% 3024
2023
Q3
$562K Sell
34,772
-67,795
-66% -$1.95M ﹤0.01% 3029
2023
Q2
$4.26M Sell
102,567
-75,264
-42% -$4.67M ﹤0.01% 2588
2023
Q1
$10.7M Buy
177,831
+12,948
+8% +$1.03M ﹤0.01% 2204
2022
Q4
$12.1K Buy
164,883
+2,543
+2% +$191K ﹤0.01% 2112
2022
Q3
$12.3M Buy
162,340
+18,148
+13% +$1.42M ﹤0.01% 2075
2022
Q2
$10M Buy
144,192
+16,759
+13% +$1.26M ﹤0.01% 2191
2022
Q1
$10.6M Buy
127,433
+2,534
+2% +$187K ﹤0.01% 2272
2021
Q4
$9.38M Buy
124,899
+2,760
+2% +$277K ﹤0.01% 2335
2021
Q3
$14.2M Sell
122,139
-1,003
-0.8% -$152K ﹤0.01% 2169
2021
Q2
$27.3M Sell
123,142
-37,052
-23% -$7.21M 0.01% 1903
2021
Q1
$21.2M Sell
160,194
-4,120
-3% -$652K 0.01% 2005
2020
Q4
$28.4M Buy
164,314
+6,883
+4% +$942K 0.01% 1791
2020
Q3
$17.5M Buy
157,431
+7,232
+5% +$578K 0.01% 1919
2020
Q2
$8.9M Buy
150,199
+1,574
+1% +$104K ﹤0.01% 2247
2020
Q1
$10M Sell
148,625
-6,013
-4% -$475K 0.01% 2118
2019
Q4
$13M Buy
154,638
+15,198
+11% +$1.23M ﹤0.01% 2248
2019
Q3
$10.4M Buy
139,440
+41,164
+42% +$3.29M ﹤0.01% 2325
2019
Q2
$6.21M Sell
98,276
-45,350
-32% -$2.3M ﹤0.01% 2576
2019
Q1
$6.92M Buy
+143,626
New +$6.91M ﹤0.01% 2536
2018
Q4
Sell
-25,242
Closed -$1.32M 3457
2018
Q3
$1.32M Buy
+25,242
New +$1M ﹤0.01% 3009

Other funds holding NVCR

Dimensional Fund Advisors's NVCR Position: Q1 2026 in Review

Dimensional Fund Advisors increased its NovoCure (NVCR) stake by 28% in Q1 2026, buying an estimated $2.6M and bringing the position to 960,056 shares worth $10.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2244.

Dimensional Fund Advisors first reported a position in NVCR in Q3 2018 and has held it in 30 quarters since. The position peaked at $28.4M in Q4 2020. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Dimensional Fund Advisors held 960,056 shares of NovoCure worth $10.5M as of Q1 2026.
  • Dimensional Fund Advisors bought 207,913 NovoCure shares in Q1 2026, an estimated $2.6M.
  • NovoCure made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #2244 holding.
  • Dimensional Fund Advisors first reported a position in NovoCure in Q3 2018 and has held it in 30 quarters since.
  • Dimensional Fund Advisors's NovoCure position peaked at $28.4M in Q4 2020.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.